iX Biopharma Ltd.

42C

SG1BD9000009

Pharmaceuticals

Market Closed - Singapore S.E. Other stock markets 09:59:22 23/05/2024 BST			5-day change	1st Jan Change
0.04 ^SGD	0.00%		-6.98%	-11.11%

03-12	Singaporean Shares End Marginally Higher; Biopharma's Shares Climb 2% on Introduction of New Sublingual Wafer	MT
03-12	IX Biopharma Introduces New Sublingual Wafer	MT

IX Biopharma Ltd. Appoints Yee Chia Hsing as Director of Corporate Affairs

March 28, 2021 at 11:07 pm

iX Biopharma Ltd. appointed Yee Chia Hsing as Director of Corporate Affairs, iX Biopharma Ltd. GM of Entity Health. Executive. Promote corporate profiling of the company and Entity Health brand among various stakeholders. He will also assist CEO on various matters as may be needed.

Latest news about iX Biopharma Ltd.

Singaporean Shares End Marginally Higher; Biopharma's Shares Climb 2% on Introduction of New Sublingual Wafer	03-12	MT
IX Biopharma Introduces New Sublingual Wafer	03-12	MT
IX Biopharma Ltd. Announces Development of Semaglutide Sublingual Wafer, Ixb 401, Targeting Diabetes and Obesity Markets	03-11	CI
Singapore Stocks Linger in Red; IX Biopharma's Shares Soar 12% Following Unveiling of Novel Drug Delivery System	03-05	MT
IX Biopharma Unveils Novel Drug Delivery System; Shares Surge 12%	03-05	MT
Singapore Stocks Open on Monday in Red; IX Biopharma’s Stock Plunge 9% Following Contract Termination	03-04	MT
IX Biopharma Ltd. Unveils Novel NAD Wafers At the Centre for Healthy Longevity Conference 2024	03-04	CI
IX Biopharma’s Subsidiary Issues Termination Notice for Licensing Agreement; Shares Plunge 9%	03-04	MT
IX Biopharma Stays in Red in Fiscal H1	02-06	MT
IX Biopharma Ltd. Reports Earnings Results for the Half Year Ended December 31, 2023	02-05	CI
IX Biopharma Unit Ends Wafermine Licensing Deal with Seelos Therapeutics; Shares Tumble 10%	11-20	MT
IX Biopharma Unit Launches Anti Ageing Products in US	02/10/23	MT
IX Biopharma Ltd Announces its Wholly-Owned Subsidiary, Meltmed Inc, Introduces its New Suite of Fast-Dissolving Wafer Products in United States	29/09/23	CI
Singapore Stocks Snap Losing Streak; Oxley Shares Slip 4% on Expected Losses in Fiscal H2, Fiscal 2023	22/08/23	MT
IX Biopharma Trims Losses in Fiscal H2; Shares Jump 17%	22/08/23	MT
IX Biopharma Ltd. Reports Earnings Results for the Full Year Ended June 30, 2023	21/08/23	CI
IX Biopharma Limited Unveils Development of Interferon Wafer to Complement Respiratory Viral Diseases	16/08/23	CI
IX Biopharma Ltd. Announces Change of Registered Office Address	04/08/23	CI
IX Biopharma Issues SG$2 Million Worth of Convertible Bonds to Private Investor	25/07/23	MT
IX Biopharma Ltd. announced that it has received SGD 2 million in funding	23/07/23	CI
IX Biopharma Gets Regulatory Nod to List Over 24 Million Shares; Shares Drop 5%	18/07/23	MT
IX Biopharma to Issue SG$2 Million Worth of Convertible Bonds	04/07/23	MT
IX Biopharma Ltd. announced that it expects to receive SGD 2 million in funding	02/07/23	CI
IX Biopharma Turns to Loss in July-December 2022 as Revenue Plummets 81%	10/02/23	MT
IX Biopharma Concludes Phase 1 Study on Dementia Treatment Drug	10/02/23	MT

Chart iX Biopharma Ltd.

Duration

Period

More charts

Company Profile

IX Biopharma Ltd. is a Singapore-based specialty pharmaceutical and nutraceutical company. The Company is focused on the development, manufacturing and commercialization of innovative therapies for the treatment of acute and breakthrough pain, and other health conditions. It has developed a patented drug delivery platform technology, WaferiX. WaferiX is a novel multi-drug delivery platform comprising a highly porous, amorphous and non-ionic matrix in a solid dosage form. The Company operates through two segments: Specialty Pharmaceutical and Nutraceutical segments. Specialty Pharmaceutical primary business activities are the development, manufacturing and sale of pharmaceutical and medicinal cannabis products. Nutraceutical primary business activities are the sale of nutraceutical products. The Company's pipeline of products under development includes Wafermine (ketamine wafer) and BnoX (buprenorphine wafer) for pain management.

Sector

Pharmaceuticals

Calendar

18/08/2024 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
IX BIOPHARMA LTD.	-11.11%	22.77M
ELI LILLY AND COMPANY	+38.69%	723B
NOVO NORDISK A/S	+34.28%	595B
JOHNSON & JOHNSON	-4.49%	369B
MERCK & CO., INC.	+20.24%	332B
ABBVIE INC.	+2.12%	282B
ASTRAZENECA PLC	+17.02%	244B
NOVARTIS AG	+9.31%	208B
ROCHE HOLDING AG	-5.07%	205B
PFIZER, INC.	-0.35%	168B

Other Pharmaceuticals

iX Biopharma Ltd.

Equities

42C

SG1BD9000009

Pharmaceuticals

IX Biopharma Ltd. Appoints Yee Chia Hsing as Director of Corporate Affairs

Latest news about iX Biopharma Ltd.

Chart iX Biopharma Ltd.

Company Profile

Income Statement Evolution

Annual profits - Rate of surprise

Sector Other Pharmaceuticals